세계의 유전성 강직성 하반신마비 시장 : 유형별, 치료별, 투여 경로별, 유통 채널별, 환자별, 지역별

Hereditary Spastic Paraplegia Market is estimated to be valued at USD 181.4 Mn in 2025 and is expected to reach USD 456.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.

Hereditary spastic paraplegia (HSP) represents a diverse group of inherited neurological disorders characterized by progressive weakness and spasticity of the lower limbs, stemming from degeneration of corticospinal tract axons. The global hereditary spastic paraplegia market encompasses pharmaceutical interventions, medical devices, diagnostic tools, and therapeutic services designed to manage this complex condition affecting approximately 3-10 individuals per 100,000 worldwide. With over 80 identified genetic subtypes classified as either pure or complicated forms, HSP presents significant clinical heterogeneity that drives demand for personalized treatment approaches. The market landscape is evolving rapidly due to advancing genetic testing capabilities, improved understanding of disease pathophysiology, and emerging therapeutic modalities including gene therapy and novel pharmacological interventions. Current treatment paradigms primarily focus on symptom management through antispastic medications, physical therapy, and assistive devices, while research pipelines increasingly emphasize disease-modifying therapies.

Market Dynamics

The global hereditary spastic paraplegia market growth is primarily driven by increasing disease awareness and improved diagnostic capabilities, particularly through advanced genetic testing technologies that enable earlier and more accurate identification of HSP subtypes. Rising healthcare expenditure in developed nations, coupled with growing investment in rare disease research and development, significantly propels market expansion as pharmaceutical companies and biotechnology firms allocate substantial resources toward developing targeted therapies. Moreover, increasing research and development coupled with regulatory approval is expected to augment the market over the analysis period. For instance, on April 28, 2025, BlackfinBio Ltd, a clinical stage gene therapy company focused on the development of treatments for rare neurological diseases, announced that the U.S. Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application for a Phase 1/2 clinical trial of its novel adeno-associated virus (AAV) gene therapy, BFB-101, in children with Hereditary Spastic Paraplegia Type 47 (SPG47). SPG47 is a rare, autosomal-recessive, neurological disorder characterized by progressive lower-limb spasticity, developmental delays and intellectual disability in children.

Key Features of the Study

• This report provides in-depth analysis of the global hereditary spastic paraplegia market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global hereditary spastic paraplegia market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Teva Pharmaceuticals USA, Inc., Amneal Pharmaceuticals LLC, Piramal Pharma Limited (PPL), Camber Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., Nexus Pharmaceuticals, LLC, AdvaCare Pharma, Pfizer Inc., Genentech, Inc. (F. Hoffmann-La Roche AG), AbbVie Inc., Merz Pharmaceuticals, LLC., Ipsen Biopharmaceuticals, Inc., and Other Prominent Players.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global hereditary spastic paraplegia market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hereditary spastic paraplegia market.

Market Segmentation

• Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Pure
  • Complicated
• Therapeutics Insights (Revenue, USD Mn, 2020 - 2032)
  • Muscle Relaxants
  • Baclofen
  • Tizanidine
  • Dantrolene
  • Pain Management
  • Gabapentin or Pregabalin
  • Benzodiazepines
  • Diazepam
  • Clonazepam
  • Botulinum Toxin Injections
  • Others (Anticholinergic medications, etc.)
• Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
  • Oral
  • Parenteral
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Patient Demographics Insights (Revenue, USD Mn, 2020 - 2032)
  • Adults
  • Pediatrics
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online Pharmacies
  • Retail Pharmacies
  • Hospitals Pharmacy
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Teva Pharmaceuticals USA, Inc.
  • Amneal Pharmaceuticals LLC
  • Piramal Pharma Limited (PPL)
  • Camber Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • Nexus Pharmaceuticals, LLC
  • AdvaCare Pharma
  • Pfizer Inc.
  • Genentech, Inc. (F. Hoffmann-La Roche AG)
  • AbbVie Inc.
  • Merz Pharmaceuticals, LLC.
  • Ipsen Biopharmaceuticals, Inc.
  • Other Prominent Players

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Hereditary Spastic Paraplegia Market, By Type
  • Global Hereditary Spastic Paraplegia Market, By Therapeutics
  • Global Hereditary Spastic Paraplegia Market, By Route of Administration
  • Global Hereditary Spastic Paraplegia Market, By Distribution Channel
  • Global Hereditary Spastic Paraplegia Market, By Patient Demographics
  • Global Hereditary Spastic Paraplegia Market, By Distribution Channel
  • Global Hereditary Spastic Paraplegia Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• PEST Analysis
• Industry Trends
• Epidemiology
• Treatment Option Analysis
• Reimbursement Scenario
• Disease Awareness Programs
• Pipeline Analysis
• Technology Landscape

4. Global Hereditary Spastic Paraplegia Market, By Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pure
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Complicated
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Hereditary Spastic Paraplegia Market, By Therapeutics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Muscle Relaxants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Baclofen
  • Tizanidine
  • Dantrolene
• Pain Management
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Gabapentin or Pregabalin
• Benzodiazepines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Diazepam
• Clonazepam
• Botulinum Toxin Injections
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Anticholinergic medications, etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Hereditary Spastic Paraplegia Market, By Route of Administration, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Hereditary Spastic Paraplegia Market, By Patient Demographics, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Adults
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Pediatrics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Hereditary Spastic Paraplegia Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hospitals Pharmacy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Hereditary Spastic Paraplegia Market, By Region, 2021 - 2032, Value (USD Mn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Mn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country, 2021 - 2032, Value (USD Mn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Type, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Therapeutics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Route of Administration, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Patient Demographics, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Distribution Channel, 2021 - 2032, Value (USD Mn)
  • Market Size and Forecast, By Country/Region, 2021 - 2032, Value (USD Mn)
    • South Africa
    • North Africa
    • Central Africa

11. Competitive Landscape

• Teva Pharmaceuticals USA, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Amneal Pharmaceuticals LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Piramal Pharma Limited (PPL)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Camber Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• ANI Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Nexus Pharmaceuticals, LLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AdvaCare Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genentech, Inc. (F. Hoffmann-La Roche AG)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merz Pharmaceuticals, LLC.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ipsen Biopharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Other Prominent Players
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us